HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintains a $50 price target.
May 25, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Pliant Therapeutics and maintains a $50 price target.
The reiterated Buy rating and maintained $50 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Pliant Therapeutics. This news is likely to have a positive short-term impact on the stock price as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100